Eisai and Pfizer Announce FDA Approval for New Higher-Dose Aricept Tablet for the Treatment of Moderate to Severe

Specific to moderate to severe Alzheimer's disease.

Eisai Inc. and Pfizer Inc [NYSE: PFE] announced today that the U.S. Food and Drug Administration (FDA) approved a new once-daily, higher-dose Aricept (donepezil HCl) 23 mg tablet for the treatment of moderate-to-severe Alzheimer’s disease (AD). Aricept 23 mg tablet offers another dosing option for patients with moderate-to-severe AD, for whom few treatments are available.
Original content Bob DeMarco, the Alzheimer's Reading Room